Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice President, Investor
Search Results for: Teva
It’s time to see Teva Pharmaceuticals (TEVA) from a different perspective
Shares of Teva Pharmaceuticals (NYSE: TEVA) fell to a new low this month as markets across the world continued to be battered
Teva Pharmaceutical (TEVA) swings to profit in Q4, beats estimates
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) swung to a profit in the fourth quarter of 2019 from a loss last year, helped
Teva Q3 profit misses estimates, tightens FY19 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019 as generic competition hurt Copaxone revenue
Teva’s Q2 results beat market expectations
Teva Pharmaceutical Industries (NYSE: TEVA) topped revenue and earnings estimates for the second quarter of 2019, giving shares a lift of 1.4%
Earnings preview: Teva’s struggles might not end in Q2
Teva Pharmaceuticals (NYSE: TEVA) is scheduled to report second quarter 2019 earnings results on Wednesday, August 7, before market open. Analysts expect
Teva Pharma sinks on Q1 revenue miss amid generic competition; earnings beat
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as the company
Earnings preview: New product launches in focus as Teva gets ready for Q1 report
Teva Pharmaceutical (NYSE: TEVA) has long endued uncertainties in business even as the generic drug maker continued its efforts to tackle high
Earnings: Teva Pharma shrinks Q4 losses, but revenue falls
Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56
Earnings Preview: Positive sentiment around Teva
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report fourth-quarter 2018 earnings results on Wednesday, February 13, before market open. Wall Street
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed expectations on
Earnings Preview: It’s a mixed bag for Teva Pharma in Q3
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to post its third-quarter 2018 earnings on Nov 1, before the opening bell. So, what
Teva Pharma receives a booster shot with FDA approval
The US FDA on Thursday approved Teva Pharmaceuticals’ (TEVA) generic version of EpiPen and EpiPen Jr auto-injector for the emergency treatment of
Teva Pharmaceuticals shares take a tumble despite earnings beat
Teva Pharmaceutical Industries Ltd. (TEVA) beat market estimates on adjusted EPS for Q2 2018 while revenues came in line with expectations. Despite
US generic drug market throttles Teva Pharmaceuticals as revenue slips
Teva Pharmaceuticals Industries Ltd. (TEVA) reported a decrease of 10% in revenues to $5.1 billion for the first quarter of 2018 compared
Accenture PLC (NYSE: ACN) Q2 2020 Earnings Call Transcript
Accenture PLC (NYSE: ACN) Q2 2020 Earnings Conference Call Corporate Participants: Angie Park -- Managing Director & Head of Investor Relations Julie Sweet -- Chief Executive Officer
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as investor mood
Mylan under pressure as shortage of anti-allergy injector persists
Pharmaceutical company Mylan (Nasdaq: MYL), which has been facing criticism for the short supply of its anti-allergy injector EpiPen, suffered a jolt
What the future holds for generic drug industry
The size of the generic drug market in the US is so large that about 90% of all prescription medicines sold last
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across all markets,